InvestorsHub Logo
icon url

joenatural

10/23/09 3:31 PM

#7519 RE: BiotechValues #7517

The financing was back in the Spring, but the restatement of EPS last quarter was due to accounting reasons surrounding warrants, etc. This was all disclosed back on August 19th and it didn't stop the stock from reaching new highs and even these new recent highs are a pimple on the face of a giant. The raised guidance from yesterday indicates EPS of .92 for 2009 with 50% growth in revenues each year for the next three years .......

"Not knocking the stock..but wasn't three some dilution last q that caused a decline in eps just reported?"